A sarbecovirus distantly related to SARS-CoV-2 and found in horseshoe bats in Russia is able to enter human cells using the ACE2 receptor, according to research published in PLOS Pathogens.
The new tailored doses against Omicron have arrived just in time for the upcoming autumn and winter wave. Although we do not know which variant will circulate in the coming months, these vaccines are safe and will help reduce transmission in what could be difficult months from a care pressure point of view.
The Minister of Health, Carolina Darias, responded yesterday in the government control session in Congress to a parliamentary question that face masks will continue to be obligatory on public transport. According to Darias, the Alerts Committee justifies the measure "due to the high concentration of people in very small spaces, without adequate ventilation and on long journeys".
Psychological distress, including depression, anxiety, worry, perceived stress and loneliness, prior to covid-19 infection was associated with an increased risk of persistent covid, according to research published in JAMA Psychiatry.
To estimate the effectiveness of two or three doses of vaccines against covid-19 infection and hospitalisation, researchers in Denmark conducted a study of all previously uninfected Danish residents aged 12 years and older. The conclusion of the research, which is published in PLOS Medicine, is that a third dose provided greater protection against infection and hospitalisation with omicron than two vaccines.
A study published in the New England Journal of Medicine has analysed the effectiveness of the antiviral drug Paxlovid after implantation of the omicron variant. The relative risk of severe disease decreased markedly in patients over 65 years of age, both vaccinated and unvaccinated. No differences were found in those under 65 years of age.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of the covid-19 vaccine manufactured by Moderna that also targets the omicron variant. It is intended to serve as a booster dose for adults.
The European Medicines Agency (EMA) is still considering the approval of Hipra's SARS-CoV-2 vaccine. In mid-May, Hipra said it was ready to "have the vaccine available in a few days" following EMA approval, which it expected by the middle of this year, but which is being delayed until at least after July, as Elia Torroella, Hipra's R&D and Registration Director, explained at a breakfast briefing organised by the company today.
The WHO's Global Influenza Surveillance and Response System recorded outliers for influenza illness in 16 countries, including Spain, in early 2020. This would mean an average of 13 weeks before the first reported covid-19 peak, according to research published in PLoS Medicine.
Results from a survey of more than 39,000 menstruating individuals reveal that 42% experienced heavier bleeding after SARS-CoV-2 vaccination. Among the most likely groups were pre-menopausal women, Hispanic or Latina women, those who had been pregnant, and those with conditions such as endometriosis and polycystic ovary syndrome.